Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • US govt demands more pricing info on Gilead HCV pill

    The cost of Gilead Sciences’ hepatitis C pill Sovaldi is once again under the spotlight with the US Senate Finance Committee requesting detailed pricing information.

    15 July 2014 | Pharma Times
  • Obamacare's Surprising HIV Drug Demand

    The Affordable Care Act has established basic core health requirements for insurance plans offered in the U.S. that support those diagnosed with life-threatening chronic diseases, including HIV. As a result, Express Scripts has reported that demand for drugs used to treat HIV and prevent HIV transmission grew in the first quarter because of rising enrollment in both marketplace plans and the expansion of Medicaid in many states.

    14 July 2014 | Motley Fool
  • Zombie patents

    Drug companies are adept at extending the lifespan of patents, at consumers’ expense

    25 June 2014 | The Economist
  • HCV drug out of the running

    The German pharmaceutical giant Boehringer Ingelheim is stopping development of faldaprevir, its hepatitis C virus (HCV) drug.

    23 June 2014 | MedPage Today
  • A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi

    In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.

    23 June 2014 | Reuters
  • UNITED STATES: FDA Approves AbbVie's Hepatitis C Regimen for Priority Review

    The US Food and Drug Administration (FDA) has granted priority review for AbbVie’s experimental all-oral regimen for treating adults infected with hepatitis C virus (HCV). The drug’s application under priority review means that FDA must evaluate the safety and effectiveness of the AbbVie regimen within six months before letting the manufacturer know whether they may take the product to market. AbbVie’s new regimen consists of an antiviral called ritonavir and a protease inhibitor called ABT-450, combined with an NS5A inhibitor called ombitasvir and the polymerase inhibitor dasabuvir. When taken together, these mechanisms are powerful enough to stop HCV. [Article source:]

    19 June 2014 | CDC
  • Dolutegravir in HIV-1 infection: Added benefit in adult patients

    The German Institute for Quality and Efficiency in Health Care (IQWiG) has determined that the new integrase inhibitor drug dolutegravir (Tivicay ®) is of considerable added benefit to treatment-naive patients in comparison with current first-line therapies, and some added benefit to patients who already need to take an integrase inhibitor.

    19 June 2014 | Science Daily
  • South Africa: Litigation threat may prompt access to cheaper DR-TB drug

    South Africa may finally allow access to a cheaper form of the drug-resistant tuberculosis (DR-TB) drug linezolid following the lodging of a high court case.

    16 June 2014 | Health-e
  • NICE consults on draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C

    In draft recommendations published today healthcare guidance body NICE is asking Gilead Sciences for more information on its product sofosbuvir (Sovaldi), for the treatment of chronic hepatitis C. “The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients. However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer.”

    16 June 2014 | NICE press release
  • Boehringer gets ‘kite mark’ for health information

    Germany-based Boehringer Ingelhiem has become the first pharma company to be awarded The Information Standard (TIS) certification for the healthcare information it provides to patients, their families and carers.

    13 June 2014 | PM Live
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.